SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe First People's Hospital of Lianyungang
About this trial
To evaluate the efficacy and safety of SRT combined with anlotinib in the treatment of limited brain metastases from non-small cell lung cancer.
Eligibility criteria
Qualifiers
Patients voluntarily participate in this study, sign informed consent, and demonstrate good compliance.
Patients with histologically or pathologically confirmed EGFR wild-type and EGFR mutant non-small cell lung cancer resistant to treatment.
The number of brain metastases is ≤ 5, and the patient has at least one assessable brain metastasis on imaging (RECIST 1.1). Additionally, the patient's physical condition allows for the completion of stereotactic radiosurgery.
Age between 18-80 years, gender unspecified.
Disqualifiers
Patients with diffuse pleural metastases, malignant pericardial effusion, or diffuse spinal cord involvement.
Patients with a history of other malignancies within 5 years (excluding cured basal cell carcinoma of the skin, prostate intraepithelial neoplasia, and cervical intraepithelial neoplasia).
Current presence of pulmonary pneumonia with CTCAE 5.0 grade ≥ 2.
Individuals with various factors that affect oral medication (such as dysphagia, gastrointestinal resection, chronic diarrhea, and intestinal obstruction).
Trial design
Treatments tested in this trial
- Anlotinib hydrochloride
Treatment groups
46 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov